Literature DB >> 24293375

N stages of the seventh edition of TNM Classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy.

Jingyu Deng1, Rupeng Zhang, Yuan Pan, Baogui Wang, Liangliang Wu, Xishan Hao, Han Liang.   

Abstract

The objective of this study was to explore the prognostic prediction rationality of the seventh edition N stage for gastric cancer (GC) patients who underwent the limited lymphadenectomy. Clinicopathological data of 769 GC patients who underwent the curative resection between 1997 and 2006 were analyzed for demonstration that the seventh edition N stage had the significant superiorities of prognostic prediction to the patients who underwent the limited lymphadenectomy. Although the extent of lymphadenectomy was associated with the overall survival (OS) of gastric cancer (GC) patients, the N stages of the seventh edition of the TNM Classification were identified as the most intensively independent predictors of GC prognosis. Using stratum analysis, the 5-year survival rate of patients who underwent limited lymphadenectomy was observed to be significantly different from that of patients who underwent extended lymphadenectomy, regardless of the extent of lymph node metastasis. Multinomial logistic regression analysis revealed that combining the extents of lymph node metastasis and lymphadenectomy could improve the prediction accuracy of patient survival status. Case control analysis showed that regardless of the extent of lymphadenectomy, the seventh edition N stages featured significant superiority for OS evaluation of GC patients. The seventh edition N stage had the prediction rationality for the OS of GC patients who underwent the limited lymphadenectomy.

Entities:  

Mesh:

Year:  2013        PMID: 24293375     DOI: 10.1007/s13277-013-1428-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence.

Authors:  Jingyu Deng; Han Liang; Dan Sun; Rupeng Zhang; Hongjie Zhan; Xiaona Wang
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

2.  The prognostic analysis of lymph node-positive gastric cancer patients following curative resection.

Authors:  Jingyu Deng; Han Liang; Dan Sun; Yi Pan
Journal:  J Surg Res       Date:  2009-01-10       Impact factor: 2.192

3.  Discussion of the applicability of positive lymph node ratio as a proper N-staging for predication the prognosis of gastric cancer after curative surgery plus extended lymphadenectomy.

Authors:  Jingyu Deng; Han Liang
Journal:  Ann Surg       Date:  2012-12       Impact factor: 12.969

4.  First drainage lymph node(s) in gastric cancer: analysis of the topographical pattern of lymph node metastasis in patients with pN-1 stage tumors.

Authors:  Shiro Kikuchi; Atsushi Kurita; Katada Natsuya; Shinichi Sakuramoto; Nobuyuki Kobayashi; Hitoshi Shimao; Akira Kakita
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

5.  Superiority of a new UICC-TNM staging system for gastric carcinoma.

Authors:  H Hayashi; T Ochiai; T Suzuki; H Shimada; S Hori; A Takeda; Y Miyazawa
Journal:  Surgery       Date:  2000-02       Impact factor: 3.982

6.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

7.  Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma.

Authors:  C W Wu; M C Hsieh; S S Lo; S H Tsay; W Y Lui; F K P'eng
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

8.  Gastric cancer treatment guidelines in Japan.

Authors:  Toshifusa Nakajima
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

9.  Lymphadenectomy in gastric carcinoma. A prospective and prognostic study.

Authors:  J Jaehne; H J Meyer; H Maschek; H Geerlings; E Burns; R Pichlmayr
Journal:  Arch Surg       Date:  1992-03

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  6 in total

1.  TFF3 and HER2 expression and their correlation with survival in gastric cancer.

Authors:  Jianchun Gu; Leizhen Zheng; Li Zhang; Siyu Chen; Meiling Zhu; Xiaoping Li; Yajie Wang
Journal:  Tumour Biol       Date:  2014-12-17

Review 2.  Clinical significance of lymph node metastasis in gastric cancer.

Authors:  Jing-Yu Deng; Han Liang
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

3.  Preoperative predicting score of lymph node metastasis for gastric cancer.

Authors:  Yanjun Zhang; Zhi Zhu; Zhe Sun; Zhenning Wang; Xinyu Zheng; Huimian Xu
Journal:  Tumour Biol       Date:  2014-07-23

4.  Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer.

Authors:  Wenyang Pang; Neng Lou; Cancan Jin; Changyuan Hu; Chandoo Arvine; Guangbao Zhu; Xian Shen
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-05       Impact factor: 2.566

5.  The overexpression of MDM4: an effective and novel predictor of gastric adenocarcinoma lymph node metastasis.

Authors:  Junjie Bao; Abiyasi Nanding; Haibin Song; Rui Xu; Guofan Qu; Yingwei Xue
Journal:  Oncotarget       Date:  2016-10-11

6.  The value of preoperative lymphocytes-to-monocytes ratio in predicting lymph node metastasis in gastric cancer.

Authors:  Dexiao Du; Ziliang Han; Dongbo Lian; Buhe Amin; Wei Yan; Nengwei Zhang
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.